RE:RE:I'll make the call on it now: LABS and VerdeMed are in M&Amdj, I was thinking about their IPO plans and in the environment of cannabis stocks in general. The IPO could be a big flop considering how badly the "pot" sector was hammered and investor appetite just might not be there for an IPO as well as shorts piling onto it knowing it's a "pot" stock. I wonder which brokerage firm will be doing the IPO for them and how many pounds of flesh they want from VerdeMed?
Pidduck emphasized 2 things in the CC....generic Epidiolex and M&A at existing valuations.
Nice to know that Eurofarma is the generic Epidiolex partner in Brazil...they have a nice global foot print as well.
ps: It's a small world isn't it...below from Wiki and the partnership to produce COVID vaccines in Brazil for Pfizer. On 26 August 2021, Pfizer Inc. and BioNTech, the developers of the COMIRNATY vaccine against COVID-19, announced a partnership with Eurofarma